iFIT Adds More Ways to Workout, Brings Club Pilates and YogaSix Content to Its Platform
5.6.2025 15:00:00 CEST | Business Wire | Press Release
iFIT Inc., a global leader in intelligent, personalized fitness, today announced a new partnership with Xponential Fitness to bring iFIT members access to premium Pilates and yoga content from Club Pilates and YogaSix. This collaboration expands iFIT’s Emmy-nominated fitness library, offering members more diverse, studio-quality workouts from two of the most popular fitness brands in the boutique space.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605386786/en/
New partnership brings more dynamic strength and mobility-focused classes to iFIT’s platform.
With this addition, iFIT members can now incorporate Club Pilates and YogaSix classes into their personalized training regimens, supporting a more well-rounded, sustainable, and enjoyable approach to fitness. The content focuses on movements you can do at home on a yoga mat, complementing iFIT’s vast library of immersive outdoor content members can enjoy on their treadmill, studio bike, rower or elliptical.
“We’re incredibly excited to bring the Club Pilates and YogaSix experiences to our Athletes,” said Jeremy McCarty, Chief Subscription Officer at iFIT Inc. “As a leader in connected fitness, we’re constantly evolving to meet the needs of our Athletes. With this partnership, our Athletes now get access to a broader range of fitness content—all included as part of their iFIT membership.”
Meet the New Additions:
Club Pilates delivers low-impact, full-body Reformer-based Pilates workouts that strengthen and lengthen the muscles and improve posture. Designed for everyone from beginners to fitness lovers, Club Pilates is ideal for any strength, cross-training, injury recovery, or prenatal or postpartum wellness routine, making it a choice fitness modality for every BODY.
YogaSix redefines the yoga experience with modern yoga classes focused on strength, balance, mobility, and mind-body connection. Each class invites participants to grow at their own pace, offering both physical and mental benefits while creating a supportive and energizing community.
“This partnership with iFIT, a pioneer in connected fitness, allows us to bring our world-class content to a wider audience than ever before,” said Steve Pankowski, EVP of Strategic Partnerships at Xponential Fitness. “By leveraging iFIT’s innovative platform and expansive global reach, we’re proud to introduce the transformative experiences of Club Pilates and YogaSix to millions of members around the world in a truly immersive, digital-first way.”
What’s Next:
As part of the launch, iFIT will feature Club Pilates and YogaSix classes in a member Challenge, celebrating the new content with fresh opportunities for motivation and progress. Any eligible iFIT member who completes the challenge will receive a Club Pilates intro class pass (in studio) and be entered into a drawing to receive an annual membership to Club Pilates or YogaSix.*
About iFIT Inc.
iFIT Inc. is a global leader in fitness technology, pioneering connected fitness to help people live longer, healthier lives. With a community of more than 6 million athletes around the world, iFIT delivers immersive, personalized workout experiences at-home, on the go, and in the gym. Powered by a comprehensive ecosystem of proprietary software, innovative hardware, and engaging content, the iFIT platform brings fitness to life through its portfolio of brands: NordicTrack, ProForm, Freemotion, and the iFIT app. From cardio and strength training to recovery, iFIT empowers athletes at every stage of their fitness journey. For more information, visit iFIT.com.
About Club Pilates & YogaSix
Founded in 2007, Club Pilates is the largest Pilates brand by number of studios, designed with the vision of making Pilates more accessible, approachable and welcoming to everyone. Based in Irvine, CA, Club Pilates has appeared in both Entrepreneur Magazine's Franchise 500 and Fastest-Growing Franchises nine years running and Inc. Magazine's Inc. 5000 lists multiple times. Club Pilates offers extensive training certification for its instructors. Its 500-hour training program. Club Pilates is headquartered in Irvine, CA and backed by Xponential Fitness, one of the leading global franchisors of boutique health and wellness brands. To learn more about Club Pilates, visit https://www.clubpilates.com.
About YogaSix
Founded in 2012, YogaSix is the largest franchised yoga brand in the United States that offers a broad range of heated and non-heated yoga classes, strength-building and cardio-boosting fitness classes, and restorative yoga classes accessible to all. YogaSix has six Signature class formats, including Y6 101, Y6 Restore, Y6 Slow Flow, Y6 Signature Hot and Warm, Y6 Power Flow, and Y6 Sculpt & Flow, plus three Specialty Classes: Y6 Mix, Y6 TRX, and the new Y6 Mobility. Classes at YogaSix eliminate the intimidation factor that many people feel when trying yoga for the first time, offering a fresh perspective on one of the world's oldest fitness practices. Ranked in Entrepreneur Magazine’s Franchise 500 three years running, and Fastest-Growing Franchises and Top New Franchises two years running, YogaSix is headquartered in Irvine, California, and backed by Xponential Fitness, one of the leading global franchisors of boutique health and wellness brands. To learn more about YogaSix, visit www.yogasix.com.
*NO PURCHASE NECESSARY. Open only to current iFIT subscribers who are residents of the United States or Canada, excluding Quebec; age 18+. Available from June 5, 2025 at 12:01 am MT through July 31, 2025 at 11:59 pm MT. To enter, must complete designated iFIT workouts and submit an entry form prior to July 31, 2025 at 11:59 pm MT. Limit 1 entry and 1 prize per person. Not transferable. Not to be combined with any offer. Subject to Offer Terms. Sponsor: iFIT Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250605386786/en/
Contacts
ICR for iFIT Inc.
iFIT@icrinc.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom